Irreversible Uuo Model
Irreversible Uuo Model - Related Videos
14:05
A Murine Model of Irreversible and Reversible Unilateral Ureteric Obstruction
0 Views •
Cited by 47 •
2014
The murine model of irreversible unilateral ureteric obstruction (UUO) is presented together with the model of reversible UUO in which the ureteric obstruction is relieved by anastomosis of the severed ureter into the bladder. These models enable the study of renal inflammation and scarring as well as tissue remodeling.
03:50
Irreversible Electroporation: A Technique for Ablating Pancreatic Tumor in Mouse
0 Views •
2023
This video describes the procedure for performing irreversible electroporation (IRE) for non-thermal ablation of pancreatic tumors in mice. Both subcutaneous (SQ) and orthotopic tumors can be successfully treated with IRE in a highly controlled setting, facilitating various studies post-procedure.
01:14
Reversible and Irreversible Processes
0 Views •
2023
The thermodynamic processes can be classified into reversible and irreversible processes. The processes that can be restored to their initial state are called reversible processes. It is only possible if the process is in quasi-static equilibrium, i.e., it takes place in infinitesimally small steps, and the system remains at equilibrium However, these are ideal processes and do not occur naturally. An ideal system undergoing a reversible process is always in thermodynamic equilibrium within...
08:05
A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation
0 Views •
Cited by 11 •
2018
Irreversible electroporation (IRE) is a non-thermal ablation technique used for the treatment of locally advanced pancreatic cancer. Being a relatively new technique, the effects of IRE on the tumor growth are poorly understood. We have developed a syngeneic mouse model that facilitates studying the effects of IRE on pancreatic cancer.
06:17
Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
0 Views •
2025
The quantitative irreversible tethering (qIT) assay is a fluorescence-based method of identifying covalent fragments that selectively engage with a target protein. Here, a detailed protocol is outlined to describe the qIT assay, with example results included.
FAQs
The model requires clearly identified variables, assumptions, and transition rules before its behavior can be assessed. Variables should describe the system’s relevant starting conditions and the lasting states it may reach. Without these elements, the name alone does not establish what changes are represented or how medical observations should be interpreted.
Transition rules define how the modeled system moves from one state to another and whether a return to an earlier state is permitted. In the Irreversible Uuo Model, these rules are especially important because the framework is intended to represent lasting change. Their explicit formulation allows researchers to examine whether the model’s conclusions follow from its assumptions.
The distinction affects how researchers interpret movement between states. A reversible framework may allow a system to return to an earlier condition, whereas an irreversible framework emphasizes a lasting transition. For the Irreversible Uuo Model, this comparison clarifies which conclusions depend on nonreturn assumptions and prevents researchers from treating all observed changes as interchangeable.
A lack of an established medical definition limits interpretation. Researchers should not infer a mechanism, input, or validated application from the term itself. Instead, they must identify the model’s assumptions and transition rules, then determine whether its behavior has been evaluated against relevant observations. This protects disease or treatment interpretations from unsupported extrapolation.
First, specify the medical process being represented, the variables that describe it, and the transitions the model permits. Next, state the assumptions governing lasting change and identify the intended outcome, such as disease progression or treatment response. Only after these elements are explicit can the framework be examined for relevance or consistency.
It could provide a way to organize observations involving changes that do not readily return to their starting condition. For disease progression, the model would need defined states and transition rules; for treatment response, it would need specified inputs and outcomes. The provided information does not establish validated medical applications, so these uses remain conditional.
The available description does not identify a specific output, measurement, or prediction. Its potential information would depend on the variables, transition rules, and assumptions selected by the investigator. Those choices might organize disease or treatment-related changes, but researchers must define and evaluate the resulting interpretation rather than assume that the framework supplies a standard clinical result.
Reports should identify the model’s precise meaning in the study, its variables, assumptions, transition rules, and intended medical interpretation. They should also state whether the framework has been validated for the condition or response being examined. Because the term lacks a sufficiently established medical definition in the provided information, transparent limitations are essential when presenting conclusions.